HER2-LOW BREAST CANCER
Clinical trials for HER2-LOW BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-LOW BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-LOW BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…
Matched conditions: HER2-LOW BREAST CANCER
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New combo aims to tackle Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase 2 trial tests a combination of two drugs—disitamab vedotin and bevacizumab—in 37 people with HER2-low metastatic breast cancer whose disease progressed after prior T-DXd therapy. The goal is to see if the combo can shrink tumors and delay progression. Researchers will …
Matched conditions: HER2-LOW BREAST CANCER
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug shows promise for Hard-to-Treat breast cancers in Real-World study
Disease control Recruiting nowThis study is tracking 300 people with HER2-positive or HER2-low breast cancer who are receiving trastuzumab-rezetecan as part of their routine care. Researchers are monitoring side effects and how well the drug works in real-world conditions, not in a strict lab setting. The goa…
Matched conditions: HER2-LOW BREAST CANCER
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for hard-to-treat breast cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called BL-M07D1 against standard chemotherapy in 566 adults with HER2-low breast cancer that has come back or spread. The goal is to see if BL-M07D1 can slow the cancer's growth better than current treatments. Participants must be women aged 18 to 75 w…
Matched conditions: HER2-LOW BREAST CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug shows promise for Hard-to-Treat breast cancers in Real-World setting
Disease control Recruiting nowThis study is tracking 800 Chinese patients with advanced HER2-positive or HER2-low breast cancer who are receiving trastuzumab deruxtecan (T-DXd) in real-world clinics. Researchers want to see how long patients stay on treatment and how well it works outside of clinical trials. …
Matched conditions: HER2-LOW BREAST CANCER
Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can switching drugs outsmart breast cancer? new trial tests two targeted therapies
Disease control Recruiting nowThis phase 2 trial is testing two antibody-drug conjugates—trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan (Dato-DXd)—in people with HER2-negative metastatic breast cancer whose disease has worsened after prior antibody-drug conjugate therapy. Participants will receiv…
Matched conditions: HER2-LOW BREAST CANCER
Phase: PHASE2 • Sponsor: Ana C Garrido-Castro, MD • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New scan could match breast cancer patients to best therapy
Diagnosis Recruiting nowThis study tests a special PET scan that uses a radioactive tracer to detect HER2 protein on cancer cells. The goal is to see if this scan can better identify which patients with metastatic breast cancer will benefit from a targeted drug called T-DXd. About 70 women with advanced…
Matched conditions: HER2-LOW BREAST CANCER
Sponsor: Renske Altena • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
Scientists map genetic landscape of HER2-Low breast cancer to unlock survival clues
Knowledge-focused Recruiting nowThis observational study looks at 255 women with HER2-low breast cancer to understand how certain gene changes (HRD/HRR) relate to survival. Researchers will analyze tumor and blood samples to map these genetic features. The goal is to learn more about this cancer type, not to te…
Matched conditions: HER2-LOW BREAST CANCER
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC